目的：利用基因工程方法获得SEREX肿瘤抗原基因原核表达蛋白，为进一步血清学分析奠定基础。方法：采用SEREX方法，筛选中国人卵巢癌CDNA表达文库。对获得的3个阳性克隆基因MY-0v A-2、MY-0VA-7和MY_0vA-13，利用基因工程的方法克隆其全长基因，原核表达和亲和层析获得目的蛋白，并采用Dot-blot的方法初步检测了目的蛋白抗原在正常人和肿瘤患者中的血清学反应格局。结果：获得了纯化的目的蛋白，采用点杂交对13例正常人和74例肿瘤患者血清的测定结果显示，MY-0vA-13的抗体只在肿瘤组中检测到，在正常组中为阴性；MY-0vA-2和MY-0vA-7在两组人群的血清中自身抗体检出率均呈现阳性，不同的肿瘤类型的阳性率各不相同。结论：基因工程获得的蛋白质抗原可望成为肿瘤的血清学诊断工具。

目的：鉴定CTL识别的HLA2A2限制性人卵巢癌相关抗原OVA66表位。方法：以细胞因子从外周血单个核细胞（PBMC）中诱导树突状细胞（DC），通过形态学观察和流式细胞术进行鉴定。用表位预测法选取并合成两种肽分子，分别脉冲成熟的DC，并刺激HLA2A2+健康人自体CD8+T细胞。1wk后，用脉冲肽的自体PBMC以每7 d的间隔刺激该CD8+T细胞3次。以共接受4次抗原肽刺激的T细胞作为CTL，用乳酸脱氢酶（LDH）释放试验，检测CTL对靶细胞的杀伤效应。用酶联免疫斑点法（EL ISPOT），检测CTL中抗原特异性分泌IFN2γ的T细胞数。结果：形态学和流式细胞术的结果显示，PBMC可诱生成熟的DC肽L235（FLPDH IN IV）诱导的CTL，可特异性杀伤L235脉冲的T2细胞和OVA66+、HLA2A2+的SW480细胞，且L235诱导的特异性分泌IFN2γ的T细胞数增加。结论：卵巢癌相关抗原OVA66的HLA2A2限制性CTL表位L235，能激发对肿瘤抗原的特异性免疫应答，为制备肿瘤特异性肽疫苗奠定了实验基础。

Bcl-xL is a well characterized death-suppressing molecule of the Bcl-2 family. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia. In this study, we used a novel approach to study the potential neuroprotective effect of Bcl-xL as a therapeutic agent in the murine model of focal ischemia/reperfusion. We created a Bcl-xL fusion protein, designated as PTD-HA-Bcl-xL, which contains the protein transduction domain (PTD) derived from the human immunodeficiency TAT protein. We demonstrated that this fusion protein is highly efficient in transducing into primary neurons in cultures and potently inhibited staurosporininduced neuronal apoptosis. Furthermore, intraperitoneal injection of PTD-HA-Bcl-xL into mice resulted in robust protein transduction in neurons in various brain regions within 1-2 hr, and decreased cerebral infarction (up to 40%) in a dosedependent manner, as determined at 3 d after 90 min of focal ischemia. PTD-HA-Bcl-xL was effective even when it was administered after the completion of ischemia (up to 45 min), and the protective effect was independent of the changes in cerebral blood flow or other physiological parameters. Finally, as shown by immunohistochemistry, Western blotting, and substrate-cleavage assays, PTD-HA-Bcl-xL attenuated ischemiainduced caspase-3 activation in ischemic neurons. These results thus confirm the neuroprotective effect of Bcl-xL against ischemic brain injury and provide the first evidence that the PTD can be used to efficiently transduce a biologically active neuroprotectant in experimental cerebral ischemia.

目的探讨人卵巢癌细胞体外刺激、诱导的肿瘤特异细胞毒性T淋巴细胞（CTL）对靶细胞的杀伤活性。方法应用建株的人卵巢癌细胞（OVA 319），在体外定期刺激、诱导肿瘤患者外周血淋巴细胞，经微量淋巴细胞毒试验和流式细胞术分别测定扩增的淋巴细胞组织相容性白细胞抗原（HLA）I娄分子表型和膜表面免疫标志物，并通过4-甲基偶氯唑盐（MTT）法分析其对肿瘤细胞的杀伤活性。结果经卵巢癌细胞刺激、诱导3周后扩增的淋巴细胞主要为T细胞抗原受体（TCR）α、β及CDB阳性的CTL，具有明显特异性杀伤肿瘤细胞的作用，并发现经OVA-319细胞刺激、诱导后不同个体的卵巢癌患者CTL的杀伤活性与教靶细胞的HLA A、B位点机同数成正比。结论肿瘤细胞体外激活的CTL具有特异系伤靶细咆作用，提不CTL特异杀伤作用与刺激细胞、靶细胞及本身CTL表现的HLA-A、B位点密切联系。

目的探索肾透明细胞癌与HLA-A，B抗原之问的关联。方法HLA-A，B抗原分型采用常规NIH标准微量淋巴细胞毒方法。结果11例肾透明细胞癌患者A2，A9和B40等位基因的表达高于正常人。结论提示肾透明细胞癌患者可能与某些HLA等位基因存在着一定的疾病关联。